Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Medigen Vaccine Biologics's Revenue for the
three
months ended in Mar. 2026 was NT$105.9 Mil. Medigen Vaccine Biologics's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$123.2 Mil.
Hence, Medigen Vaccine Biologics's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.86.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Medigen Vaccine Biologics Receivables Turnover Related Terms
Medigen Vaccine Biologics Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Vaccine Biologics (ROCO:6547) has a Receivables Turnover of 0.86 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medigen Vaccine Biologics and its competitors. According to the industry distribution chart, Medigen Vaccine Biologics ranks #496 out of 841 companies in the Biotechnology industry, placing it in the top 59%.
Is Medigen Vaccine Biologics' Receivables Turnover too high?
Medigen Vaccine Biologics' current Receivables Turnover is 0.86. The Biotechnology industry median Receivables Turnover is 5.27. Medigen Vaccine Biologics' value of 0.86 is 83.7% below this industry median. Based on the distribution chart, Medigen Vaccine Biologics ranks #496 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medigen Vaccine Biologics has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #496 out of 841 companies for Receivables Turnover. This places Medigen Vaccine Biologics in the lower half of its industry. The industry median Receivables Turnover is 5.27. Medigen Vaccine Biologics' value of 0.86 is 83.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Vaccine Biologics's current Receivables Turnover of 0.86 is 83.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medigen Vaccine Biologics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Vaccine Biologics's current Receivables Turnover is 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$58.34, compared to a current price of NT$51.60 — trading 11.6% below its estimated fair value. The current Receivables Turnover is 0.86 and 83.7% below the Biotechnology industry median of 5.27. Medigen Vaccine Biologics' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Receivables Turnover is 0.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued.
The current stock price of NT$51.60 is trading 11.6% below its estimated GF Value™ of NT$58.34.
GuruFocus considers Medigen Vaccine Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:6547:
Receivables Turnover: 0.86
GF Value™: NT$58.34 vs. price of NT$51.60 (11.6% below fair value)
Industry Position: 83.7% below the Biotechnology median (#496 of 841)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
67GF Score
Get the complete analysis for ROCO:6547
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
